Additional file 2 of Causality of genetically determined metabolites on anxiety disorders: a two-sample Mendelian randomization study

Additional file 2: Table S1. The formula used to calculate R2 and F statistic between exposure and outcome; Table S2. Summary statistics of the anxiety disorders; Table S3–S12. Mendelian Randomization estimation for Amino acid(Table S3); Carbohydrate (Table S4); Co-factor or vitamin(Table S5);Energy(Table S6); Lipid(Table S7); Nucleotide (Table S8); Peptide (Table S9); Xenobiotic(Table S10);X(unknow metabolites) (Table S11);known metabolites (Table S12) on the risk of anxiety disorders; Table S13. The characteristics of SNPs and their genetic associations with known metabolites and the anxiety disorders; Table S15. The reverse MR analysis of 1-linoleoylglycerophosphoethanolamine and anxiety disorders using various methods; Table S16. Association of 1linoleoylglycerophosphoethanolamine and additional anxiety disorders GWAS using various methods; Table S14, S17–S21. Summary statistics for the associations of the five metabolites (passed all the sensitivity analyses)-associated SNPs with these exposures and the anxiety disorders from MRC-IEU Consortium; Table S22. Metabolic Pathway Associated with self-reported anxiety; Table S23. Clinical characteristics of participants involved in the study; Table S24. Characteristics of the KORA population related to antihypertensives and lipid-lowering drugs; Table S25. Characteristics and patterns of anti-hyperglycemic treatment of participants with self-reported type 2 diabetes in the KORA F4 study.附加文件2：表S1：用于计算暴露因素与结局间R²与F统计量的公式；表S2：焦虑障碍汇总统计数据；表S3~S12：针对焦虑障碍发病风险开展的孟德尔随机化（Mendelian Randomization）分析结果，其中表S3对应氨基酸类、表S4对应碳水化合物、表S5为辅因子或维生素、表S6对应能量代谢、表S7对应脂质类、表S8对应核苷酸类、表S9对应肽类、表S10对应外源性物质、表S11对应未知代谢物（X）、表S12对应已知代谢物；表S13：单核苷酸多态性（Single Nucleotide Polymorphism, SNPs）的特征及其与已知代谢物、焦虑障碍的遗传关联；表S15：采用多种分析方法对1-亚油酰甘油磷酸乙醇胺与焦虑障碍开展的反向孟德尔随机化分析；表S16：采用多种分析方法探究1-亚油酰甘油磷酸乙醇胺与新增焦虑障碍全基因组关联研究（Genome-Wide Association Study, GWAS）数据集间的关联；表S14、S17~S21：来自MRC-IEU联盟的、5种通过全部敏感性分析的代谢物相关SNPs与上述暴露因素及焦虑障碍间关联的汇总统计数据；表S22：与自我报告焦虑症状相关的代谢通路；表S23：本研究纳入参与者的临床特征；表S24：KORA人群中与降压药物及调脂药物相关的特征；表S25：KORA F4研究中自我报告2型糖尿病参与者的降糖治疗特征与模式。